Findings from this study support use of serial MRD monitoring during lenalidomide maintenance therapy to identify patients likely to benefit from prolonged treatment.
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
Researchers presented initial results from an ongoing, phase 3, randomized study of once-weekly SVd vs twice-weekly Vd after 1 to 3 prior anti-multiple myeloma regimens.
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
Researchers reported significant improvements in 5-year relative survival among older patients with multiple myeloma who were diagnosed from 1982 to 2017.
Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
Guidance is provided regarding possible treatment plan alterations for older patients with multiple myeloma based on COVID-19 infection risk.
Darzalex Faspro is a new subcutaneous formulation that contains daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase, an endoglycosidase.
Differential effect seen by race, with significantly lower OS for white but not African-American patients.
Previous mostly retrospective/observational studies evaluated low-dose aspirin administered once daily in the setting of ET. In this study, the more frequent dosing was found optimal.
The SKY92 MMprofiler assay evaluates the expression of 92 multiple myeloma-related genes.
Investigators found that SC administration of daratumumab was noninferior to IV administration, and patient satisfaction appeared to be higher in the SC group.
An expanding range of treatment options in the past decade has led to greater long-term survival in patients with multiple myeloma.
In recent years, the NCCN has updated its clinical practice guidelines to include MRD assessment for MM, ALL, and CLL.
While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Prior therapy with lenalidomide and shorter disease history were found to correlate with poorer outcomes.
The FDA has approved Sarclisa (isatuximab-irfc; Sanofi), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
For patients with newly diagnosed multiple myeloma, a less frequent dosing regimen of bortezomib may elicit a similar clinical response.
In this study, 1 of the criteria for defining intermediate- or high-risk smoldering multiple myeloma was clonal bone marrow plasma cells between 10% and less than 60%.
Patients who were enrolled in clinical trials that employed a total therapy protocol had a lower early mortality rate compared with patients not on a total therapy protocol.
For biologically effective dose ≤28 Gy
10, small but significant increase seen in reirradiation rates
Researchers compared the monoclonal immunoglobulin rapid accurate measurement and matrix-assisted laser desorption/ionization-time of flight assays.
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Progression-free survival, overall survival, and percentage of patients who achieved very good partial response or better were similar between both treatment groups.
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Frailty score based on age, Charlson Comorbidity Index, ECOS PS predicts outcomes in FIRST trial.
The presence of circulating tumor plasma cells by next-generation flow independently predicted disease progression after treatment in patients with multiple myeloma.
Cardiopulmonary adverse events with carfilozmib treatment included dyspnea, hypertension, peripheral edema, cough, pneumonia, and heart failure.
Patients who received isatuximab experienced a median progression-free survival of 11.5 months compared with 6.5 months in patients who did not receive isatuximab.
Long-term follow-up from the clinical trial investigating LCAR-B38M, a BCMA-targeting CAR-T, revealed that approximately three-quarters of patients achieved a complete response.
This dose-finding study examined a bispecific antibody targeting BCMA and CD3 in patients with R/R multiple myeloma.
The addition of plerixafor to treatment following transplantation may not enhance lymphocyte recovery in patients with multiple myeloma.
Only about one-third of patients required hospital admission.
Researchers developed and tested a risk stratification model based on hematopoietic variables that can be obtained from a complete blood count.
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Patients who received intensification treatment experienced longer progression-free survival compared with patients receiving maintenance treatment.
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
Progression-free survival significantly longer with lenalidomide compared with observation
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
Increased hospital activity unrelated to hematology seen for years before diagnosis
Time to initiation of therapy was significantly longer for black and Hispanic patients compared with white patients.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Prolonged closure time and defects in von Willebrand factor were identified as risk factors for bleeding complications patients with multiple myeloma.
Researchers conducted a subgroup analysis of Asian patients with relapsed or refractory multiple myeloma who received carfilzomib in 2 phase 3 clinical trials.
A critical step in the preparation of autologous CAR-T therapy is the ex vivo proliferation of T cells from samples obtained from leukapheresis.
In this systematic review, researchers analyzed the cost effectiveness of various treatments and treatment lines for multiple myeloma.